Automating Allergy & Immunology Biologics Prior Auth

For allergy and immunology practices, managing prior authorizations for high-cost biologics is a significant operational challenge. Klivira streamlines **allergy & immunology biologics prior auth** to accelerate patient access and optimize revenue cycles.

The increasing utilization of biologics and specialty therapies in allergy & immunology, including agents for severe asthma, atopic dermatitis, and chronic urticaria, directly impacts administrative burden. These medications often require complex, indication-specific prior authorization processes that consume valuable staff time and delay critical treatment. Efficiently navigating these requirements is crucial for both patient care continuity and financial performance.

The Challenge of Biologics PA in Allergy & Immunology

Biologics such as Xolair, Dupixent, and Nucala, alongside IVIG and other advanced immunotherapies, represent a substantial portion of high-cost specialty drug prior authorizations in allergy & immunology. These therapies address conditions like severe asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis. The administrative overhead stems from complex payer criteria, including indication-specific requirements, step therapy protocols, and documentation of diagnostic results like IgE levels or eosinophil counts.

Typical Prior Authorization Triggers in Allergy & Immunology

In allergy & immunology, prior authorization is commonly triggered by the prescription of high-cost biologics and specialty pharmaceuticals. This includes asthma biologics, IVIG/SCIG, and allergen immunotherapy. Payer policies frequently mandate specific diagnostic criteria, documentation of prior line therapies, and periodic re-authorization cycles based on patient response and disease activity. This complexity contributes significantly to the administrative burden, as highlighted by industry benchmarks like the CAQH Index which tracks specialty pharmacy PA volume.

Klivira's Automated Workflow for Allergy & Immunology Biologics Prior Auth

**Indication Classification:** Automatically identifies the specialty and specific disease state (e.g., severe asthma, atopic dermatitis) from EMR diagnoses to apply relevant PA criteria.
**Step Therapy Automation:** Pulls prior-line therapy history (e.g., controller therapy for asthma, topical treatments for dermatitis) from the EMR to fulfill step therapy requirements.
**Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, routing requests based on preferred biosimilar options where applicable.
**Screening Documentation:** Extracts necessary screening results, such as TB or hepatitis status, from FHIR-enabled EMR data to meet payer requirements.
**Periodic Re-authorization:** Manages typical 6- or 12-month re-authorization cycles by documenting continuous disease activity and treatment response.
**Medical-vs-Pharmacy Benefit Routing:** Accurately routes prior authorization requests based on whether the biologic is covered under medical or pharmacy benefits, often depending on the mode of administration.

EMR and Payer Integration for Allergy & Immunology

Klivira integrates directly with leading EMR systems via SMART on FHIR to extract critical clinical data, including diagnoses, lab results (e.g., IgE levels, eosinophil counts, PFTs), and medication history. This data populates X12 278 and ePA submissions, streamlining communication with payer portals and leveraging standards like Da Vinci PAS. This approach minimizes manual data entry, reduces errors, and accelerates the prior authorization process for allergy & immunology practices.

Evidence-Based PA and Clinical Guidelines

Klivira's automation platform is designed to align with evidence-based clinical guidelines relevant to allergy & immunology, such as those from GINA (Global Initiative for Asthma) or the AAAAI/ACAAI. By ensuring that submitted documentation reflects established criteria for severe asthma, atopic dermatitis, and other conditions, Klivira helps clinics demonstrate medical necessity efficiently. This reduces the likelihood of denials and supports compliance considerations.

Frequently asked questions

What specific biologics does Klivira automate PA for in Allergy & Immunology?

Klivira automates prior authorizations for a range of high-cost biologics and specialty therapies commonly used in allergy & immunology, including Xolair, Dupixent, Nucala, and IVIG/SCIG, as well as other asthma biologics and advanced immunotherapies.

How does Klivira handle step therapy requirements for allergy biologics?

Our platform automates the verification and documentation of step therapy requirements by pulling prior-line therapy history directly from the EMR. This ensures that all necessary previous treatments are accurately recorded and submitted with the prior authorization request, aligning with payer policies.

Can Klivira manage re-authorizations for chronic biologic therapy?

Yes, Klivira supports the management of periodic re-authorizations for chronic biologic therapies. The system tracks re-authorization cycles and prompts for necessary documentation, such as ongoing disease activity and patient response, to facilitate timely renewals and prevent treatment interruptions.

What EMR data does Klivira use for allergy & immunology biologics prior auth?

Klivira leverages comprehensive EMR data, including patient diagnoses, relevant lab results (e.g., IgE levels, eosinophil counts, PFTs), prior medication history, and screening documentation (e.g., TB status). This data is securely extracted via FHIR integrations to build complete and accurate PA submissions.

How does Klivira address medical vs. pharmacy benefit routing for biologics?

Klivira's workflow is designed to identify and correctly route prior authorization requests based on whether the biologic is covered under the medical or pharmacy benefit. This distinction often depends on the mode of administration and ensures that submissions go to the appropriate payer channel for faster processing.